Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2024 · 50 positions · Total reported value $2.37B · Top-10 concentration 58.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2024 13F filing, Frazier Life Sciences Management, L.P. disclosed 50 equity positions with a combined reported value of $2.37B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 58.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were NAMS ($289.17M), KRYS ($175.88M), MIRM ($163.16M). By sector, the heaviest allocations are Health Care 73.5%, Materials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+2.4pp) and away from Other (-2.6pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 77% of names.

The largest new positions opened in Q1 2024 were CGON ($33.80M), PEPG ($22.09M), ADVM ($15.12M).

Of the 3 positions fully exited versus the prior quarter, the largest were MDGL ($16.06M), DYN ($15.76M), CRNX ($14.14M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • CGON CG ONCOLOGY INC · $33.80M
  • PEPG PEPGEN INC · $22.09M
  • ADVM ADVERUM BIOTECHNOLOGIES INC · $15.12M
  • PBYI PUMA BIOTECHNOLOGY INC · $14.93M
  • APLT APPLIED THERAPEUTICS INC · $13.28M
  • ALLO ALLOGENE THERAPEUTICS INC · $12.82M
  • MGX METAGENOMI THERAPEUTICS INC · $2.94M

Fully Exited (vs previous quarter)

  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $16.06M
  • DYN DYNE THERAPEUTICS INC · prev qtr: $15.76M · history
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $14.14M
  • APGE APOGEE THERAPEUTICS INC · prev qtr: $11.18M
  • THRX THERAVANCE INC · prev qtr: $8.58M
  • MRTX MIRATI THERAPEUTICS INC · prev qtr: $4.70M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 73.5%
Materials 0.2%
Other 26.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.23M $289.17M 12.20%
12.20%
Add
2 988.46K $175.88M 7.42%
7.42%
Hold
3 6.50M $163.16M 6.88%
6.88%
Hold
4 9.78M $162.67M 6.86%
6.86%
Hold
5 3.13M $124.11M 5.24%
5.24%
Hold
6 10.11M $107.36M 4.53%
4.53%
Hold
7 3.42M $105.61M 4.46%
4.46%
Add
8 2.19M $94.90M 4.00%
4.00%
Reduce
9 8.79M $87.06M 3.67%
3.67%
Hold
10 1.14M $77.83M 3.28%
3.28%
Reduce
11 1.79M $64.98M 2.74%
2.74%
Hold
12 3.30M $60.26M 2.54%
2.54%
Add
13 4.14M $56.96M 2.40%
2.40%
Add
14 885.16K $52.03M 2.19%
2.19%
Hold
15 785.00K $48.87M 2.06%
2.06%
Hold
16 3.01M $48.50M 2.05%
2.05%
Hold
17 3.69M $43.74M 1.85%
1.85%
Add
18 1.56M $42.06M 1.77%
1.77%
Add
19 875.67K $37.48M 1.58%
1.58%
Add
20 2.47M $36.38M 1.53%
1.53%
Add
21 1.20M $35.63M 1.50%
1.50%
Hold
22 770.00K $33.80M 1.43%
1.43%
New
23 746.48K $33.61M 1.42%
1.42%
Hold
24 997.46K $32.15M 1.36%
1.36%
Hold
25 4.62M $29.50M 1.25%
1.25%
Add
26 629.19K $26.97M 1.14%
1.14%
Add
27 7.38M $25.46M 1.07%
1.07%
Hold
28 1.15M $24.81M 1.05%
1.05%
Add
29 1.46M $22.90M 0.97%
0.97%
Add
30 1.50M $22.09M 0.93%
0.93%
New
31 899.70K $20.26M 0.85%
0.85%
Hold
32 4.00M $19.92M 0.84%
0.84%
Hold
33 393.00K $16.61M 0.70%
0.70%
Hold
34 523.17K $15.30M 0.65%
0.65%
Hold
35 1.07M $15.12M 0.64%
0.64%
New
36 2.82M $14.93M 0.63%
0.63%
New
37 832.22K $13.65M 0.58%
0.58%
Reduce
38 1.95M $13.28M 0.56%
0.56%
New
39 2.87M $12.82M 0.54%
0.54%
New
40 285.33K $11.78M 0.50%
0.50%
Hold
41 1.00M $11.64M 0.49%
0.49%
Reduce
42 470.34K $8.70M 0.37%
0.37%
Reduce
43 936.58K $6.29M 0.27%
0.27%
Reduce
44 203.68K $5.60M 0.24%
0.24%
Hold
45 500.33K $5.52M 0.23%
0.23%
Hold
46 1.39M $4.51M 0.19%
0.19%
Hold
47 279.02K $2.94M 0.12%
0.12%
New
48 1.03M $2.65M 0.11%
0.11%
Hold
49 1.71M $2.19M 0.09%
0.09%
Hold
50 264.38K $327.83K 0.01%
0.01%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2024-Q1?

In its 2024-Q1 13F filing, Frazier Life Sciences Management, L.P. reported 50 equity positions worth $2.37B in aggregate; its largest disclosed positions were NAMS ($289.17M), KRYS ($175.88M), MIRM ($163.16M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $2.37B of long equity holdings across 50 positions as of 2024-Q1. Top-10 holdings account for 58.6% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →